3 Reasons to Buy AbbVie Stock Like There's No Tomorrow

💡 Key Takeaway

AbbVie's post-Humira recovery, driven by Skyrizi and Rinvoq, a deep pipeline including weight-loss and eczema drugs, and a strong dividend make it a compelling long-term buy.

What Happened: AbbVie's Post-Humira Strategy Pays Off

AbbVie's stock is up 10% year-to-date, slightly outperforming the S&P 500. Despite the patent loss of its former blockbuster Humira in 2023, the company quickly resumed revenue growth thanks to its immunology drugs Skyrizi and Rinvoq.

These two drugs are expected to generate over $31 billion in combined revenue this year, exceeding management's original 2027 target of $27 billion. They have successfully filled the gap left by Humira and face no biosimilar competition until at least 2033.

AbbVie is also investing in future growth. It is developing ABBV-295, a weight-loss therapy that showed promising early results, and recently acquired Apogee Therapeutics for $10.9 billion to gain zumilokibart, a potential eczema treatment with a convenient dosing schedule.

Additionally, AbbVie maintains a strong dividend, having increased payouts for over 50 consecutive years, making it a Dividend King. The forward yield of 2.7% is well above the S&P 500 average.

icon

What This Means for Me

If you hold AbbVie, this news reinforces the stock's long-term value; consider holding or adding on dips. Investors with exposure to competitors like Amgen or Johnson & Johnson may see AbbVie's pipeline as a competitive threat. For those without healthcare exposure, AbbVie offers a balanced growth and income opportunity.

Why It Matters: AbbVie's Growth Drivers and Dividend Appeal

For investors, AbbVie's ability to rebound from Humira's patent loss demonstrates strong management and a diversified portfolio. The outperformance of Skyrizi and Rinvoq provides a solid revenue base for the next decade, reducing reliance on any single drug.

The pipeline, including weight-loss and eczema treatments, positions AbbVie for long-term growth in high-demand markets. The weight-loss market alone is projected to exceed $100 billion, offering significant upside if ABBV-295 succeeds.

AbbVie's dividend program is a key attraction for income-focused investors. With a 2.7% yield and consistent increases, it offers a reliable income stream that can enhance total returns over time.

However, risks remain. Humira sales continue to decline, and pricing pressure on Imbruvica from government negotiations could hurt revenue. Investors should monitor these headwinds, but the overall outlook is positive for those with a long-term horizon.

icon

Stock to Watch

StocksImpactAnalysis
ABBV
Positive
Strong revenue recovery post-Humira, exceptional Skyrizi/Rinvoq performance, promising pipeline, and strong dividend.
ABT
Neutral
Mentioned only as AbbVie's former parent for dividend history; no direct impact from this news.
APGE
Positive
Acquired by AbbVie at a premium; its key asset zumilokibart strengthens AbbVie's immunology pipeline.

Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.

icon

Bobby Insight

bobby-insight

AbbVie is a strong buy for long-term investors seeking growth and income.

AbbVie has successfully navigated the Humira patent cliff, with Skyrizi and Rinvoq driving robust revenue growth. Its pipeline, including weight-loss and eczema therapies, offers significant future potential. The dividend is reliable and growing, making it attractive for total return.

What This Means for Me

means-for-me
If you hold AbbVie, this news reinforces the stock's long-term value; consider holding or adding on dips. Investors with exposure to competitors like Amgen or Johnson & Johnson may see AbbVie's pipeline as a competitive threat. For those without healthcare exposure, AbbVie offers a balanced growth and income opportunity.

Read More